Acumen Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 2836 acumenpharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals, Inc.

Acumen announces Phase 1 INTERCEPT-AD study publication - Jan 10th, 2025 1:05 pm
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - Jan 9th, 2025 1:00 pm
I-Mab Leads Our Spotlight On 3 US Penny Stocks - Dec 4th, 2024 1:04 pm
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Nov 26th, 2024 9:00 pm
Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Nov 13th, 2024 7:06 am
Q3 2024 Acumen Pharmaceuticals Inc Earnings Call - Nov 13th, 2024 3:54 am
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights - Nov 12th, 2024 12:00 pm
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - Nov 11th, 2024 9:00 pm
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Nov 6th, 2024 9:00 pm
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality - Nov 6th, 2024 1:00 pm
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - Nov 5th, 2024 9:00 pm
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference - Oct 31st, 2024 12:05 pm
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Oct 23rd, 2024 12:00 pm
3 US Penny Stocks With Market Caps Under $500M To Consider - Oct 21st, 2024 5:31 pm
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Sep 30th, 2024 8:00 pm
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease - Sep 26th, 2024 12:00 pm
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 - Sep 25th, 2024 8:00 pm
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference - Sep 3rd, 2024 8:00 pm
Q2 2024 Acumen Pharmaceuticals Inc Earnings Call - Aug 14th, 2024 3:26 am
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights - Aug 13th, 2024 11:00 am